Quotes 5-day view Delayed Nasdaq
13 159 Volume
Estimated financial data (e) (USD)
Net income 2021
Net Debt 2021
P/E ratio 2021
Net income 2022
Net Debt 2022
P/E ratio 2022
1 146 M
1 146 M
Capi. / Sales 2021
Capi. / Sales 2022
Nbr of Employees
Nuvalent, Inc. is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company is advancing a pipeline of product candidates with parallel programs in cancers driven by genomic alterations in the ROS1 and ALK kinases, along with multiple discovery-stage research programs. The Company's pipeline includes NVL-520 and NVL-655. NVL-520, is a...
All news about NUVALENT, INC.
09/20 NUVALENT, INC.(NASDAQGS : NUVL) added to S&P TMI Index
09/08 NUVALENT : Management's Discussion and Analysis of Financial Condition and Results of Oper..
09/08 NUVALENT : Net Loss Widens as Operating Expenses More Than Double in Q2
09/08 NUVALENT, INC. : Results of Operations and Financial Condition, Financial Statements and E..
09/08 Nuvalent, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Mont..
08/23 NUVALENT : JPMorgan Starts Nuvalent at Overweight With $34 Price Target
08/23 NUVALENT : Cowen Initiates Coverage on Nuvalent With Outperform Rating
08/23 NUVALENT : Piper Sandler Starts Nuvalent at Overweight With $40 Price Target
08/02 NUVALENT : Announces Closing of Upsized Initial Public Offering
08/02 NUVALENT, INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financia..
07/30 NUVALENT, INC.(NASDAQGS : NUVL) added to NASDAQ Composite Index
07/28 NUVALENT : Announces Pricing of Initial Public Offering
07/28 Nuvalent, Inc. has completed an IPO in the amount of $165.75 million.
07/06 Nuvalent, Inc. has filed an IPO in the amount of $100 million.
01/27 Nuvalent, Inc. announced that it has received $52.23494 million in funding from Deerfie..
News in other languages on NUVALENT, INC.
Analyst Recommendations on NUVALENT, INC.
Technical analysis trends NUVALENT, INC.
Short Term Mid-Term Long Term Trends Bearish Neutral Neutral
Number of Analysts
Last Close Price
Average target price
Spread / Average Target